The comparison of outcomes between hypofractionated and conventional 3D-CRT regimens used in combination with TACE as first-line treatment of advanced hepatocellular carcinoma

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Chuanxi WangJunqing Han

Abstract

Treatment of primary hepatocellular carcinoma (HCC) with transcatheter hepatic arterial chemoembolization (TACE) and three-dimensional conformal radiotherapy (3D-CRT) achieves good short-term but poor long-term survival. We retrospectively assessed whether outcomes differ between hypofractionated and conventional 3D-CRT regimens. Patients were treated in our institution between June 2005 and October 2009. All patients received two cycles of TACE followed by either hypofractionated 3D-CRT (6-8 Gy fractions for 3-4 weeks to 48-64 Gy) or conventional 3D-CRT (2 Gy fractions for 6-7 weeks to 60-70 Gy) 4 weeks later. We assessed data from 110 patients (55 in each 3D-CRT group). Overall response rates were similar in the two groups. Acute adverse event rates were not significantly higher in the hypofractionated 3D-CRT group than in the conventional 3D-CRT group; two patients and one patient, respectively, died of late radiation-induced liver failure. Overall survival at 1 year was 83.6 % in the hypofractionated 3D-CRT group versus 68.8 % in the conventional 3D-CRT group (P = 0.019), and at 3 years, it was 31.7 versus 13.9 % (P = 0.004). Median survival was 27.97 versus 16.13 months (P = 0.002). Hypofractionated 3D-CRT seemed to provid...Continue Reading

References

Aug 1, 1989·The British Journal of Radiology·J F Fowler
Mar 30, 1995·International Journal of Radiation Oncology, Biology, Physics·J D CoxT F Pajak
Feb 25, 1999·International Journal of Radiation Oncology, Biology, Physics·J SeongG E Kim
May 10, 2000·International Journal of Radiation Oncology, Biology, Physics·J C ChengC F Horng
Dec 4, 2003·Journal of Hepatology·Luigi Bolondi
Oct 28, 2004·Gastroenterology·Adrian M Di Bisceglie
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitsuhiko KawashimaTakashi Ogino
Sep 16, 2005·The New England Journal of Medicine·Jiang HePaul K Whelton
Feb 22, 2008·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·L A Dawson
Dec 9, 2008·Surgical Oncology·G Morris-StiffK R Prasad
Mar 24, 2009·International Journal of Radiation Oncology, Biology, Physics·Nobuyoshi FukumitsuKoichi Tokuuye
Jan 5, 2011·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·L-T XuL-M Liu
Jan 18, 2011·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·P Merle, F Mornex
May 31, 2011·International Journal of Radiation Oncology, Biology, Physics·Sang Min YoonDong Jin Suh
Jan 3, 2012·International Journal of Radiation Oncology, Biology, Physics·Sun Hyun BaeByung Chul Yoo
Apr 30, 2013·Journal of Gastroenterology and Hepatology·Jin-Hong ParkJong Hoon Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.